Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909439 · ClinicalTrials.gov registry record · Phase 4
Quality of Recovery After Reversal With Neostigmine or Sugammadex.
A Phase 4 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT02909439: Completed Phase 4 study, sponsored by Stony Brook University.
NCT02909439 is a Phase 4 study that has completed, run by Stony Brook University. The registered enrollment target is 80 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02909439, a Phase 4 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.
Primary Outcome
Incentive spirometry measurements will be done at 30, 60 and 120 minutes after surgery. The change from baseline and recovery profile will be measured.
Interventions
- DRUG Sugammadex
- DRUG Neostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-02 |
| Phase | Phase 4 |
What the finished NCT02909439 record still lists
NCT02909439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT02909439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02909439 about?
NCT02909439 is a clinical study titled "Quality of Recovery After Reversal With Neostigmine or Sugammadex.". This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.
What is the current status of trial NCT02909439?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2016-11. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02909439?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG).
Who is sponsoring clinical trial NCT02909439?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02909439's enrollment target sits among peer trials
80 946th of 2000 higher than 1,021 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia